Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation ...

Anthracyclines are among the most widely used chemotherapy drugs and have been a mainstay of cancer treatment for more than ...

Penile Cancer: EAU-ASCO Collaborative Guidelines Update Q and A Cancer and cardiovascular diseases are the two major causes of mortality, morbidity, and disability worldwide. The improvement in ...

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies This review critically analyzes the incidence of ...

Cardiotoxicity underlies a third of failures in regulatory clearance, making it among the most significant hurdles in developing new drugs. 1 axoCells human iPSC-derived ventricular cardiomyocytes ...

Cardiotoxicity is an important adverse effect of trastuzumab in the treatment of breast cancer. Particularly in the adjuvant setting, a high risk of cardiotoxicity is unacceptable, since the ...

The prevalence of subclinical cardiotoxicity identified by echocardiographic global longitudinal strain (GLS) in patients with breast cancer taking doxorubicin (Adriamycin) was similar whether ...

In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...

A team of investigators have discovered a genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a ...

Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials - This next-generation anthracycline demonstrates safety and promising early activity in treating multiple ...